Following this transaction, Radovich holds 27,015 shares directly. The sale was conducted to cover tax withholding obligations related to the vesting of restricted stock units. InvestingPro analysis reveals the company maintains strong liquidity with a current ratio of 3.34, while operating with moderate debt levels. Discover more insights about MIRM and access detailed Pro Research Reports covering 1,400+ top stocks through an InvestingPro subscription. InvestingPro analysis reveals the company maintains strong liquidity with a current ratio of 3.34, while operating with moderate debt levels. Discover more insights about MIRM and access detailed Pro Research Reports covering 1,400+ top stocks through an InvestingPro subscription. Following this transaction, Radovich holds 27,015 shares directly. The sale was conducted to cover tax withholding obligations related to the vesting of restricted stock units.
In other recent news, Mirum Pharmaceuticals (NASDAQ:MIRM) has been making significant strides, as reflected in their robust Q3 2024 results. The company's net sales saw a 25% quarterly increase, reaching $59.1 million, mainly driven by the impressive sales of LIVMARLI, a drug used to treat Alagille syndrome and progressive familial intrahepatic cholestasis. The strong performance prompted Mirum to raise its 2024 global net product sales guidance to a range of $330 million to $335 million, reflecting a promising 86% annual growth to the midpoint.
The recent developments also include Mirum's acquisition of MRM-3379 for Fragile X syndrome treatment, in line with their strategic focus on rare genetic diseases. The company also received a breakthrough therapy designation for Volixibat for cholestatic pruritus in PBC patients. Furthermore, its CHENODAL and CTX NDA are now under priority review.
Analysts from H.C. Wainwright reaffirmed a Buy rating on Mirum Pharmaceuticals, maintaining a $66 price target. The decision was based on the company's robust sales and the upward revision of its full-year sales forecast. It's noteworthy that LIVMARLI has made a promising start in the market, with about 20 patients transitioning from clinical drug substance to treatments reimbursed by payors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.